INOVIO Pharmaceuticals
NEWS ALERT

FDA Accepts for Review INOVIO’s BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

Archive: August 2026

INOVIO to Report Second Quarter Financial Results on August 12, 2026

Posted on August 4, 2026

INOVIO to Report Second Quarter Financial Results on August 12, 2026

Posted on August 4, 2026

INOVIO Announces Pricing of $20.0 Million Public Offering

Posted on July 29, 2026

INOVIO Announces Pricing of $20.0 Million Public Offering

Posted on July 29, 2026

INOVIO Announces Proposed Public Offering

Posted on July 29, 2026

INOVIO Announces Proposed Public Offering

Posted on July 29, 2026

INOVIO to Participate in Upcoming Scientific and Investor Conferences

Posted on May 28, 2026

INOVIO to Participate in Upcoming Scientific and Investor Conferences

Posted on May 28, 2026

Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO’s Partner in China

Posted on May 21, 2026

Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO’s Partner in China

Posted on May 21, 2026

© Copyright 2026 INOVIO Pharmaceuticals. All rights reserved.